Following up on the previous post we can review selected small and mid-stocks participating in the ASCO Conference look at performance over 3 months from March 14 to June 13 including a 7% correction in the market overall. Most biotech stocks peaked in Q2 2011. See previous post for ASCO news releases. The broad based ETF IBB was up 7.65% over the same 3 mo. period and the NASDAQ was down 2.8%.
ETF (IBB $103) Up 7.65% Peak $110
Ariad (ARIA $9.64) Up 68.8% Peak $10
Endocyte (ECYT $11.87) Up 58.5% Peak $12.15
Exelixis (EXEL $8.87) Down 21% Peak $12.37
Incyte (INCY $17.45) Up 29.4% Peak $21.15
Onyx (ONXX $36.21) Flat Peak $45
Seattle Genetics(SGEN $19.53) Up 36.1% Peak $20